| scholarly article | Q13442814 |
| P50 | author | David W. Denning | Q30533462 |
| Raoul Herbrecht | Q37841047 | ||
| Noel Jean Milpied | Q55743774 | ||
| Markus Ruhnke | Q56959444 | ||
| P2093 | author name string | Eckhard Thiel | |
| Hartmut Lode | |||
| Patricia Ribaud | |||
| Denis Caillot | |||
| Andrea Haas | |||
| P2860 | cites work | Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano | Q33489568 |
| Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis | Q33980836 | ||
| Therapeutic outcome in invasive aspergillosis | Q38970340 | ||
| Fungal pulmonary infections after bone marrow transplantation: evaluation with radiography and CT. | Q40751243 | ||
| Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis? | Q41072169 | ||
| Chronic necrotizing pulmonary aspergillosis: approach to management | Q41574360 | ||
| Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus | Q42538222 | ||
| In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. | Q42538827 | ||
| In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. | Q42540459 | ||
| NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 | ||
| An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group | Q44504692 | ||
| Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project | Q45739769 | ||
| Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations | Q46010998 | ||
| Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia | Q48693586 | ||
| Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program | Q48930567 | ||
| Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. | Q52222221 | ||
| An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. | Q53349495 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery | Q57220656 | ||
| Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients | Q58840057 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| voriconazole | Q412236 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 563-571 | |
| P577 | publication date | 2002-01-22 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | |
| P478 | volume | 34 |
| Q64245308 | A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis |
| Q90254018 | A Prospective Real-World Study of the Impact of an Antifungal Stewardship Program in a Tertiary Respiratory-Medicine Setting |
| Q91777235 | A clinical approach to respiratory disease in patients with hematological malignancy, with a focus on respiratory infection |
| Q33980368 | A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan |
| Q41907424 | A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid |
| Q38879623 | A renal aspergilloma--an unusual presentation of aspergillosis in an HIV patient. |
| Q43742898 | A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections |
| Q33385491 | A risk profile for invasive aspergillosis in liver transplant recipients |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q38918614 | Adverse reactions to voriconazole. |
| Q46763769 | Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient |
| Q42627513 | Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. |
| Q46788198 | Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy |
| Q43258660 | An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients |
| Q35942379 | An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole |
| Q44183272 | An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis |
| Q36724783 | An update on the use of antifungal agents |
| Q33490772 | Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination |
| Q38858839 | Antifungal agents and liver toxicity: a complex interaction |
| Q36111677 | Antifungal chemotherapeutics |
| Q35058091 | Antifungal pharmacotherapy for invasive mould infections |
| Q37310029 | Antifungal therapeutic drug monitoring: established and emerging indications |
| Q37161793 | Antifungal therapies in the intensive care unit |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q38202581 | Antimicrobial agents, drug adverse reactions and interactions, and cancer |
| Q37048679 | Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact |
| Q40246072 | Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B. |
| Q42272291 | Aspergillosis in solid organ transplantation |
| Q39745148 | Aspergillosis of the central nervous system in a previously healthy patient that simulated Creutzfeldt-Jakob disease |
| Q48573739 | Aspergillus brain abscess in a patient with acute myeloid leukaemia successfully treated with voriconazole |
| Q35022494 | Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress? |
| Q33719294 | Aspergillus infections in transplant recipients |
| Q86220165 | Aspergillus petrous apicitis associated with cerebral and peritubular abscesses in an immunocompetent man |
| Q41441699 | Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. |
| Q34150943 | Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients |
| Q46508204 | Breakthrough Candida infections in patients receiving voriconazole. |
| Q36892465 | Breakthrough invasive pulmonary aspergillosis despite empirical voriconazole therapy for febrile neutropenia: case report and review of the literature |
| Q35101150 | British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections |
| Q33849298 | CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? |
| Q61758331 | Can combination salvage therapy for invasive aspergillosis improve patient outcome? |
| Q46653990 | Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. |
| Q37159584 | Caspofungin for treatment of invasive aspergillus infections. |
| Q84804483 | Catheter‐associated aspergillosis of the chest wall following allogeneic hematopoietic stem cell transplantation |
| Q93078617 | Central Nervous System Infections Due to Aspergillus and Other Hyaline Molds |
| Q44351295 | Central nervous system aspergillosis in allogeneic stem cell transplant recipients. |
| Q38202576 | Central nervous system infections in cancer patients and hematopoietic stem cell transplant recipients |
| Q40529408 | Cerebral aspergillosis |
| Q40503735 | Cerebral aspergillosis due to Aspergillus fumigatus in AIDS patient: first culture-proven case reported in Brazil |
| Q46396373 | Cerebral aspergillosis in the critically ill: two cases of successful medical treatment |
| Q35678997 | Changing strategies for the management of invasive fungal infections |
| Q35833407 | Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients |
| Q47645128 | Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going? |
| Q35086478 | Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population. |
| Q40407579 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. |
| Q37328834 | Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis |
| Q34546811 | Clinical hepatotoxicity associated with antifungal agents |
| Q41769001 | Clinical importance of the CYP2C19*17 variant allele for voriconazole |
| Q42413286 | Clinical pharmacodynamics and pharmacokinetics of the antifungal extended‐spectrum triazole posaconazole: an overview |
| Q36968140 | Clinical pharmacology of antifungal agents in pediatric patients |
| Q35129039 | Clinical pharmacology of antifungal compounds |
| Q35026481 | Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. |
| Q46707138 | Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients |
| Q76381447 | Combination antifungal therapy |
| Q38823930 | Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations |
| Q35647746 | Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets |
| Q35598532 | Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults |
| Q35598464 | Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults |
| Q39665005 | Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilit |
| Q89839441 | Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child-Pugh B or C Liver Disease: A Case-Control Retrospective Study |
| Q44461729 | Concomitant use of voriconazole and rifabutin in a patient with multiple infections |
| Q37173189 | Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management |
| Q37373785 | Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis? |
| Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
| Q42165120 | Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q34706880 | Current treatment options for chronic granulomatous disease |
| Q37454223 | Cytological, microbiological and therapeutic aspects of systemic infection in a dog caused by the fungus Phialosimplex caninus |
| Q40638888 | Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation. |
| Q80783454 | Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report |
| Q42432210 | Does one voriconazole breakpoint suit all Candida species? |
| Q29398696 | Echinocandin antifungal drugs |
| Q46386344 | Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis |
| Q43226497 | Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium |
| Q38385726 | Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial |
| Q57611765 | Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients |
| Q40667778 | Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani |
| Q37944001 | Efficacy and safety of current drug therapies for invasive aspergillosis |
| Q44558731 | Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome |
| Q40062960 | Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease |
| Q44519647 | Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies |
| Q36341374 | Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients |
| Q37779496 | Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort |
| Q37119029 | Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q37379973 | Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan |
| Q36880234 | Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole |
| Q36278069 | Fungal CNS infections in patients with hematologic malignancy. |
| Q38365647 | Fungal genome sequencing: basic biology to biotechnology |
| Q62241543 | Fungal infection in solid organ recipients |
| Q36382582 | Fungal infections in bone marrow transplant recipients |
| Q35038473 | Fungal infections in nontransplant patients with hematologic malignancies |
| Q37836994 | Fungal infections in severe acute pancreatitis |
| Q33896940 | Fungal infections in transplant and oncology patients |
| Q36768045 | Fungal infections of the CNS: treatment strategies for the immunocompromised patient |
| Q36616182 | Fungal pneumonia due to molds in patients with hematological malignancies |
| Q40497134 | Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study |
| Q35746695 | Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. |
| Q37307500 | Hallucinations during voriconazole therapy |
| Q46982957 | Hallucinosis as side effect of voriconazole |
| Q37904672 | Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. |
| Q34980027 | Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. |
| Q40225550 | Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results. |
| Q43144412 | High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? |
| Q37734590 | In vitro activity of anidulafungin against selected clinically important mold isolates |
| Q44340936 | In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. |
| Q52820816 | In vitro assessment of non-irritant microemulsified voriconazole hydrogel system. |
| Q36492208 | In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus |
| Q42949201 | In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. |
| Q64108338 | Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study |
| Q90086577 | Indian Antimicrobial Prescription Guidelines in Critically Ill Immunocompromised Patients |
| Q41378447 | Infectious Disease. How to bolster the antifungal pipeline |
| Q40446187 | Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. |
| Q58775551 | Invasive Aspergillosis in Children: Update on Current Guidelines |
| Q33800526 | Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study |
| Q35616161 | Invasive aspergillosis in patients with hematologic malignancies. |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q38110850 | Invasive candidiasis: update on current pharmacotherapy options and future perspectives |
| Q43533296 | Invasive pulmonary aspergillosis after solid organ transplantation: diagnosis and treatment based on 28 years of transplantation experience |
| Q46908044 | Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities |
| Q41936899 | Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum |
| Q37625418 | Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. |
| Q37454259 | Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma |
| Q42690273 | Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis |
| Q34998102 | Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection |
| Q36286439 | Management of intracranial fungal infections in patients with haematological malignancies |
| Q37810281 | Managing fungal and viral infections in pediatric leukemia |
| Q51187346 | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. |
| Q36867435 | Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. |
| Q30452373 | Modification of rapid susceptibility assay for antifungal susceptibility testing of Aspergillus fumigatus |
| Q35782813 | Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment |
| Q61758327 | Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis |
| Q34510443 | Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis |
| Q34309603 | Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and |
| Q36597431 | New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage |
| Q44081421 | New agents for treatment of invasive aspergillosis |
| Q35627629 | New and emerging antifungal agents: impact on respiratory infections |
| Q37364295 | New and investigational triazole agents for the treatment of invasive fungal infections |
| Q58404435 | New antifungal agents |
| Q30912454 | New antifungal agents: voriconazole and caspofungin |
| Q35561985 | New approaches to invasive fungal infections |
| Q46481956 | New medications for treatment of systemic mycoses |
| Q35744330 | Newer antifungal agents |
| Q33981062 | Newer systemic antifungal agents : pharmacokinetics, safety and efficacy |
| Q35270270 | Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients |
| Q82029809 | Other opportunistic infections of the central nervous system in AIDS |
| Q44827799 | Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery |
| Q35756513 | Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination |
| Q38775809 | Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy |
| Q38880522 | Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections |
| Q36730105 | Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy |
| Q36759440 | Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia |
| Q37820674 | Pharmacoeconomics of voriconazole in the management of invasive fungal infections |
| Q89890370 | Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications |
| Q47664190 | Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy |
| Q43236771 | Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients |
| Q34141420 | Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration |
| Q36536413 | Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects |
| Q36163345 | Pharmacokinetics of antifungal agents in children |
| Q46879963 | Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease |
| Q46341880 | Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. |
| Q34352014 | Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection |
| Q37641375 | Pharmacology and clinical use of voriconazole |
| Q35959476 | Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature |
| Q57533011 | Pharmacology of Systemic Antifungal Agents |
| Q34768471 | Pharmacotherapy of Candida bloodstream infections: new treatment options, new era. |
| Q92481591 | Physicochemical stability of voriconazole in elastomeric devices |
| Q44334907 | Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients |
| Q54253897 | Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis. |
| Q42285675 | Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. |
| Q43708431 | Posaconazole for treatment of refractory invasive fungal disease. |
| Q48118247 | Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q36927577 | Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring |
| Q41522687 | Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey |
| Q60175850 | Pre-Existing Liver Disease and Toxicity of Antifungals |
| Q73431989 | Prevention and therapy of fungal infections in bone marrow transplantation |
| Q36688610 | Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature |
| Q48155956 | Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). |
| Q46708009 | Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity |
| Q35941502 | Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity |
| Q44623418 | Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole |
| Q46187823 | Pulmonary aspergillosis in solid organ transplant patients: a report from Iran. |
| Q40383432 | Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry |
| Q38296370 | Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. |
| Q58477139 | Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp |
| Q35183728 | Recommendations for the treatment of fungal pneumonias |
| Q42623673 | Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis |
| Q34276700 | Resistance to antifungals that target CYP51. |
| Q46503120 | Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients |
| Q40194039 | Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. |
| Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
| Q45263865 | Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit. |
| Q51385199 | Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. |
| Q42435668 | Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients |
| Q73256320 | Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning |
| Q39215244 | Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections |
| Q56837295 | Résistance d´ Aspergillus fumigatus à plusieurs dérivés azolés |
| Q35799730 | Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients |
| Q44925292 | Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis |
| Q36271648 | Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. |
| Q42686004 | Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. |
| Q33824506 | Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy |
| Q34413393 | Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy |
| Q36757595 | Software for dosage individualization of voriconazole for immunocompromised patients |
| Q54214603 | Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. |
| Q57746013 | Squamous cell carcinoma of the skin and voriconazole therapy in lung transplant recipients: a case series |
| Q79930293 | Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injections |
| Q41010354 | Strategies for antifungal treatment failure in intensive care units |
| Q36891747 | Successful Outcome of DisseminatedFusariumInfection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia |
| Q44634373 | Successful Voriconazole Therapy of Disseminated Fusarium Solani in the Brain of a Neutropenic Cancer Patient |
| Q43125640 | Successful management of pulmonary hemorrhage and aspergillosis in a patient with acute myeloid leukemia (AML-M3). |
| Q44360460 | Successful treatment of disseminated fusariosis |
| Q35802329 | Surgery for localized pulmonary mycotic infections in patients with hematopoietic disorder |
| Q33592487 | Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods |
| Q33876645 | Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. |
| Q35585219 | Systemic Antifungal Therapy: New Options, New Challenges |
| Q44606392 | Systemic antifungal agents |
| Q34848032 | The Pathophysiology and Treatment of Candida Sepsis |
| Q44924916 | The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial |
| Q46064587 | The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus. |
| Q52896107 | The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. |
| Q79300230 | The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida |
| Q33412744 | The role of surgery in the treatment of invasive fungal infection in paediatric haematology patients: a retrospective single-centre survey |
| Q44863417 | The role of voriconazole in the treatment of emerging mycoses |
| Q36608562 | Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole |
| Q38526795 | Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. |
| Q37688257 | Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q38362057 | Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach |
| Q37833074 | Therapeutic drug monitoring of voriconazole and posaconazole |
| Q38140015 | Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. |
| Q35967453 | Therapy of systemic fungal infections. |
| Q34301534 | Topical voriconazole as a novel treatment for fungal keratitis |
| Q34576005 | Torsades de pointes associated with voriconazole use. |
| Q28277029 | Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial |
| Q37469829 | Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
| Q35573265 | Treatment of opportunistic mycoses: how long is long enough? |
| Q43252991 | Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
| Q36521993 | Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole |
| Q35954530 | Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis |
| Q44436629 | Two Cases of Cerebral Aspergillosis Successfully Treated with Voriconazole |
| Q44973763 | Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole |
| Q45017863 | Update on antifungal treatment of invasive Candida and Aspergillus infections |
| Q37892901 | Update on the optimal use of voriconazole for invasive fungal infections |
| Q38536076 | Update on the treatment of disseminated fusariosis: Focus on voriconazole. |
| Q37785548 | Updated guidelines for managing fungal diseases in hematology patients |
| Q40674435 | Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung |
| Q47700700 | Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis |
| Q35635830 | Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods |
| Q35107225 | Vascular and Cardiac Infections in End-Stage Renal Disease |
| Q92968379 | Video-assisted thoracoscopic surgery for invasive pulmonary fungal infection in haematology patients |
| Q35179545 | Voriconazole |
| Q44400539 | Voriconazole - applications and perspectives |
| Q36729599 | Voriconazole : a review of its use in the management of invasive fungal infections |
| Q44417870 | Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections |
| Q46956494 | Voriconazole at Saint Louis Hospital (Paris): Analysis of two-years of compassionate use |
| Q44564506 | Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients |
| Q44106107 | Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study |
| Q36342188 | Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial |
| Q44589171 | Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience |
| Q39196770 | Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation |
| Q37084273 | Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis |
| Q44245132 | Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. |
| Q35166823 | Voriconazole in the management of nosocomial invasive fungal infections |
| Q80783191 | Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients |
| Q44492164 | Voriconazole in the treatment of invasive mold infections in transplant recipients. |
| Q36696390 | Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia. |
| Q33577291 | Voriconazole pharmacokinetics and pharmacodynamics in children |
| Q34045383 | Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients |
| Q33613685 | Voriconazole pharmacokinetics in liver transplant recipients. |
| Q38073201 | Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review |
| Q44294733 | Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. |
| Q46826187 | Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes |
| Q37658869 | Voriconazole therapeutic drug monitoring: focus on safety. |
| Q36469807 | Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. |
| Q36849416 | Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events |
| Q46504408 | Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results |
| Q28278518 | Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial |
| Q41985408 | Voriconazole-induced photosensitivity |
| Q40189236 | Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections |
| Q37810091 | Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections |
| Q35069136 | Voriconazole: a new triazole antifungal agent |
| Q35016972 | Voriconazole: in the treatment of invasive aspergillosis |
| Q36164008 | Voriconazole: review of a broad spectrum triazole antifungal agent |
| Q33946021 | Voriconazole: the newest triazole antifungal agent |
| Q44420165 | What is the role of therapeutic drug monitoring in antifungal therapy? |
| Q51184992 | [Current indications for voriconazole in onco-hematological patients]. |
| Q46020723 | [Keratomycosis: diagnosis and therapy]. |
| Q51184997 | [Role of voriconazole in critically ill patients with invasive mycoses]. |
| Q83843523 | [Treatment of invasive fungal infections. 2005. Andalusian Infectious Disease Society] |
Search more.